Biopharma Leaders Unite To Stand With Science LEARN MORE Pfizer & BioNTech to Supply Singapore with Vaccine Candidate to Combat COVID-19 LEARN MORE U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine LEARN MORE Alibaba Cloud, Fintech Academy and Pfizer Partner to Accelerate Healthcare Innovations LEARN MORE LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer LEARN MORE RECENT PRESS RELEASES 18/03/2020 - Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older 18/03/2020 - Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch 18/03/2020 - Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns 17/03/2020 - Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine 13/03/2020 - EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study 13/03/2020 - Pfizer Outlines Five-Point Plan to Battle COVID-19 04/03/2020 - Susan Hockfield Elected to Pfizer’s Board of Directors 02/03/2020 - U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis 27/02/2020 - James Quincey Elected to Pfizer’s Board of Directors 27/02/2020 - Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer 27/02/2020 - Mylan and Pfizer Finalize Appointments to Viatris Board of Directors 25/02/2020 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 18/02/2020 - European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) 11/02/2020 - XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC 31/01/2020 - Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab) Pagination First page « First Previous page ‹ Previous Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Next page Next › Last page Last »